Last reviewed · How we verify
rimegepant 75 mg ODT (rimegepant-75-mg-odt)
Rimegepant-75-mg-odt, developed by Pfizer Inc., is a small molecule targeting CGRP receptors. It is used for the acute treatment of migraine with or without aura in adults and prevention of migraine in adults. Rimegepant-75-mg-odt has shown clinical differentiation through its efficacy and safety profile. Its commercial significance is evident with $21.2B in revenue. There are 14 trials conducted on this drug. The pipeline developments for rimegepant-75-mg-odt are not specified.
At a glance
| Generic name | rimegepant-75-mg-odt |
|---|---|
| Sponsor | Pfizer |
| Drug class | CGRP receptor antagonist |
| Target | CGRP receptors |
| Therapeutic area | Neuroscience |
| Phase | FDA-approved |
Approved indications
- Acute treatment of migraine with or without aura in adults
- Prevention of migraine in adults
Common side effects
Drug interactions
- Warfarin
- P-glycoprotein inhibitors (e.g., cyclosporine, ketoconazole)
- P-glycoprotein inducers (e.g., rifampin, St. John's Wort)
- CYP3A4 inhibitors (e.g., ketoconazole, itraconazole)
- CYP3A4 inducers (e.g., rifampin, St. John's Wort)
- Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole)
- Strong CYP3A4 inducers (e.g., rifampin, St. John's Wort)
Key clinical trials
- Long-term Safety Study of Rimegepant in Pediatric Subjects for the Acute Treatment of Migraine (PHASE3)
- A Study to Learn About the Study Medicine Called Rimegepant in Women When Used for Intermittent Prevention of Menstrual Migraine (PHASE3)
- Randomized Study in Children and Adolescents With Migraine: Acute Treatment (PHASE3)
- A Prospective Real World Study of Rimegepant in the Treatment of Migraine
- Rimegepant as Preemptive Treatment for Predictable Trigger-Induced Migraine in Adult Patients in the US (PHASE4)
- Efficacy and Safety Study of Rimegepant in Episodic Migraine Prevention With Multiple Dosing Regimens (PHASE4)
- Safety and Tolerability Study of Daily Dosing Rimegepant in Episodic Migraine Prevention (PHASE4)
- Efficacy and Tolerability of Rimegepant for the Acute Treatment of Migraine in Adults Unsuitable for Triptan Use (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- rimegepant 75 mg ODT CI brief — competitive landscape report
- rimegepant 75 mg ODT updates RSS · CI watch RSS
- Pfizer portfolio CI